Polivy PFS Data from Key Trials
Polivy (polatuzumab vedotin), an antibody-drug conjugate for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), showed a progression-free survival (PFS) improvement in its pivotal phase 2 GO29365 trial compared to historical standards. Median PFS was 7.6 months with Polivy plus bendamustine-rituximab (BR) versus 2.0-3.7 months with BR alone in prior benchmarks.[1]
Updates from Recent Phase 3 Trials
The phase 3 POLARIX trial (NCT03274492), reported in 2022 and published in the New England Journal of Medicine, tested Polivy-R-CHP (Polivy + rituximab, cyclophosphamide, doxorubicin, prednisone) as first-line therapy in previously untreated DLBCL. It met its primary endpoint with a 27% reduction in risk of disease progression, death, or relapse (hazard ratio 0.73; 95% CI, 0.57-0.95; P=0.02). Two-year PFS was 76.7% with Polivy-R-CHP versus 70.2% with R-CHOP.[2][3] This marks an improvement over R-CHOP's historical PFS rates of around 60-70% at two years in high-risk patients.
Ongoing trials like POLARGO (NCT03508609, phase 3 in relapsed DLBCL) and CEPALO (pediatric) have not yet reported mature PFS data showing further gains; topline results from POLARGO in 2023 confirmed PFS benefit but with shorter follow-up than POLARIX.[4]
How POLARIX PFS Compares to Earlier Data
| Trial | Setting | Median PFS (months) or Rate | Comparator | Improvement |
|-------|---------|-----------------------------|------------|-------------|
| GO29365 (Phase 2, 2018) | Relapsed/refractory DLBCL | 7.6 (Polivy+BR) | BR alone (~3) | 2-3x longer median PFS [1] |
| POLARIX (Phase 3, 2022) | First-line DLBCL | Not reached (2-yr: 76.7%) | R-CHOP (2-yr: 70.2%) | 23% absolute gain at 2 years; 27% risk reduction [2] |
No subsequent trials have demonstrated PFS superior to POLARIX; updates through 2024 maintain these rates without notable improvements.[5]
What About Overall Survival and Limitations
POLARIX showed no OS benefit yet (hazard ratio 0.86; P=0.26), with median OS not reached.[2] Peripheral neuropathy (40% incidence) led to dose reductions in 24% of patients, potentially capping broader use. FDA approved Polivy-R-CHP in 2023 based on PFS.[6]
Upcoming Trials and Patent Timeline
Phase 3 trials like GO29365 confirmatory extension and APOLLO (NCT04724172, follicular lymphoma) could yield 2025 PFS readouts.[4] Polivy patents expire around 2030-2033 in major markets; no challenges noted on DrugPatentWatch.com.[7]
[1]: NEJM - GO29365 (2019)
[2]: NEJM - POLARIX (2022)
[3]: FDA Approval Summary (2023)
[4]: ClinicalTrials.gov Search for Polivy
[5]: Genentech Updates (2024)
[6]: ASCO Post - POLARIX Analysis (2023)
[7]: DrugPatentWatch.com - Polivy Patents